IDH2 and oligodendroglioma: The constraint is even more pronounced in grade 3 oligodendrogliomas, where the therapeutic threshold for altering standard-of-care regimens is higher and where broad adoption of IDH inhibitors remains premature without extended survival outcomes showing durability that approaches that of established cytotoxic therapy.